Scancell Holdings plc (LON:SCLP - Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 11.40 ($0.15) and traded as low as GBX 7.85 ($0.10). Scancell shares last traded at GBX 7.97 ($0.10), with a volume of 252,161 shares changing hands.
Scancell Stock Down 1.2 %
The firm has a market cap of £83.38 million, a price-to-earnings ratio of -12.34 and a beta of 0.35. The firm has a fifty day simple moving average of GBX 8.62 and a 200-day simple moving average of GBX 11.21. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.
Scancell (LON:SCLP - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Scancell Holdings plc will post -2.5361112 EPS for the current year.
About Scancell
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
See Also
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
